Skip to content
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact
Menu
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Innovative Treatments for Liver & Pancreatic Tumors
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Platform
    • Drug Delivery Technology
  • Pipeline
    • Our Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • The Trisalus Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact

TriSalus Life Sciences® Annual Declaration of Compliance with California Law

January 3, 2024

TriSalus Life Sciences has adopted a code of conduct to address interactions involving health care professionals with respect to its products and services (“Code of Conduct”). The Code of Conduct is modeled on the AdvaMed Code and is applicable to and adopted by TriSalus Life Sciences.

The Code of Conduct is a dynamic document, which is subject to change in accordance with applicable law and as its business evolves. TriSalus Life Sciences embraces change and will make necessary changes to its Code of Conduct on an ongoing basis.

TriSalus Life Sciences believes the Code of Conduct meets the compliance goals set forth in the State of California’s Health & Safety Code 119400 – 119402. To its knowledge, TriSalus Life Sciences is, in all material respects, in compliance with the Code of Conduct and applicable law.

This declaration is made only for the purpose of compliance with California Health and Safety Code section referenced above and should not be interpreted as a declaration of compliance with any other statute or regulation.

TriSalus Life Sciences will provide its Code of Conduct and declaration as it relates to the California Health & Safety Code 119400-119402 via e-mail or hardcopy upon request. To request this information please contact us at info@TriSalusLifeSci.com or 1.888.321.5212, if you are in the U.S. or Canada; or 1.303.426.1222, if you are calling from any other location, worldwide.

© 2024 TriSalus Life Sciences, Inc. All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use
Linkedin Twitter
Linkedin Twitter
© 2023 TriSalus Life Sciences, Inc.
All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

YES
CANCEL